Wellman G C, Barrett-Jolley R, Köppel H, Everitt D, Quayle J M
Department of Cell Physiology and Pharmacology, Leicester University, University Road, Leicester LE1 9HN.
Br J Pharmacol. 1999 Oct;128(4):909-16. doi: 10.1038/sj.bjp.0702868.
1 The aim of this study was to investigate the selectivity of the ATP-sensitive potassium (K(ATP)) channel inhibitor U-37883A (4-morpholinecarboximidine-N-1-adamantyl-N'-1-cyclohexyl). Membrane currents through K(ATP) channels were recorded in single muscle cells enzymatically isolated from rat mesenteric artery, cardiac ventricle and skeletal muscle (flexor digitorum brevis). K(ATP) currents were induced either by cell dialysis with 0.1 mM ATP and 0.1 mM ADP, or by application of synthetic potassium channel openers (levcromakalim or pinacidil). 2 U-37883A inhibited K(ATP) currents in smooth muscle cells from rat mesenteric artery. Half inhibition of 10 microM levcromakalim-induced currents occurred at a concentration of 3.5 microM. 3 Relaxations of rat mesenteric vessels caused by levcromakalim were reversed by U-37883A. 1 microM levcromakalim-induced relaxations were inhibited at a similar concentration of U-37883A (half inhibition, 1.1 microM) to levcromakalim-induced KATP currents. 4 K(ATP) currents activated by 100 microM pinacidil were also studied in single myocytes from rat mesenteric artery, skeletal muscle and cardiac ventricle. 10 microM U-37883A substantially inhibited K(ATP) currents in vascular cells, but had little effect in skeletal or cardiac myocytes. Higher concentrations of U-37883A (100 microM) caused a modest decrease in K(ATP) currents in skeletal and cardiac muscle. The sulphonylurea K(ATP) channel antagonist glibenclamide (10 microM) abolished currents in all muscle types. 5 The effect of U-37883A on vascular inward rectifier (KIR) and voltage-dependent potassium (KV) currents was also examined. While 10 microM U-37883A had little effect on these currents, some inhibition was apparent at higher concentrations (100 microM) of the compound. 6 We conclude that U-37883A inhibits K(ATP) channels in arterial smooth muscle more effectively than in cardiac and skeletal muscle. Furthermore, this compound is selective for K(ATP) channels over KV and KIR channels in smooth muscle cells.
1 本研究的目的是探究ATP敏感性钾(K(ATP))通道抑制剂U-37883A(4-吗啉甲脒-N-1-金刚烷基-N'-1-环己基)的选择性。通过酶法从大鼠肠系膜动脉、心室肌和骨骼肌(趾短屈肌)分离出的单个肌细胞中记录通过K(ATP)通道的膜电流。K(ATP)电流可通过用0.1 mM ATP和0.1 mM ADP对细胞进行透析诱导产生,也可通过应用合成钾通道开放剂(左卡尼汀或匹那地尔)诱导产生。2 U-37883A抑制大鼠肠系膜动脉平滑肌细胞中的K(ATP)电流。10 μM左卡尼汀诱导电流的半数抑制浓度为3.5 μM。3 U-37883A可逆转左卡尼汀引起的大鼠肠系膜血管舒张。1 μM左卡尼汀诱导的舒张在与左卡尼汀诱导KATP电流相似浓度的U-37883A(半数抑制浓度为1.1 μM)作用下受到抑制。4 还对100 μM匹那地尔激活的大鼠肠系膜动脉、骨骼肌和心室肌单个肌细胞中的K(ATP)电流进行了研究。10 μM U-37883A显著抑制血管细胞中的K(ATP)电流,但对骨骼肌或心肌细胞几乎没有影响。更高浓度的U-37883A(100 μM)使骨骼肌和心肌中的K(ATP)电流适度降低。磺脲类K(ATP)通道拮抗剂格列本脲(10 μM)使所有肌肉类型中的电流消失。5 还研究了U-37883A对血管内向整流钾(KIR)电流和电压依赖性钾(KV)电流的影响。虽然10 μM U-37883A对这些电流几乎没有影响,但在该化合物的更高浓度(100 μM)下有一些抑制作用明显。6 我们得出结论,U-37883A对动脉平滑肌中K(ATP)通道的抑制作用比对心肌和骨骼肌更有效。此外,该化合物在平滑肌细胞中对K(ATP)通道的选择性高于KV和KIR通道。